AngloGold Ashanti’s shares rise nearly 3% as profit soars on higher gold prices
Chief Financial Officer of Zai Lab (NASDAQ:ZLAB), Chen Yajing, sold 240 American Depositary Shares of the company on November 3rd at a price of $26.831, totaling approximately $6,439. The transaction comes as Zai Lab , currently valued at around $3 billion, is preparing to release its quarterly earnings report on November 6.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was related to covering taxes upon the vesting of Restricted Share Units. On October 31st, Chen also acquired 500 shares upon vesting of Restricted Share Units.InvestingPro data shows Zai Lab holds more cash than debt on its balance sheet, with a current ratio of 3.12, indicating strong short-term financial stability despite the company not being profitable over the last twelve months. According to InvestingPro’s Fair Value assessment, the stock appears to be undervalued at its current price. Investors seeking deeper analysis can access the comprehensive Pro Research Report, available for Zai Lab and 1,400+ other US equities.
In other recent news, Zai Lab reported its Q2 2025 earnings, which revealed a notable earnings miss. The company posted a loss per share of $0.04, which was better than the anticipated loss of $0.41. However, revenue fell short of expectations, totaling $110 million compared to the forecasted $124.95 million. In a separate development, Jefferies assumed coverage of Zai Lab with a Buy rating and set a price target of $52. The research firm highlighted Zai Lab as a leading biotech company in China, focusing on commercializing global innovations and demonstrating strong research and development capabilities internationally. These recent developments provide investors with critical insights into the company’s financial performance and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.